Rafael Ruiz Quijano
Urology · Bayamon, PRNPI 1962439448
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.0%), consulting fees and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Merck at 40.7% of the total. Reporting peaked in 2020 at $1,525 and has fallen 85.7% since, to $218 in 2025.
Across 46 payments — averaging $89.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Teleflex LLC$670
- Johnson & Johnson$578
- Boston Scientific$572
- BD$260
- Pfizer$130
- plus $219 from 7 others
What the payments were for
- Consulting fees$1,52537%
- Travel & lodging$2105%
- Food & beverage$2,04950%
- Education$3158%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $1,670 |
| Teleflex LLC | 8 | $670 |
| Johnson & Johnson(2 entities) | 12 | $578 |
| Boston Scientific | 8 | $572 |
| BD | 2 | $260 |
| Pfizer | 3 | $130 |
| Tolmar, Inc. | 3 | $78 |
| Astellas Pharma US Inc | 1 | $38 |
| Pharmaand GmbH | 1 | $23 |
| PBG Puerto Rico LLC | 1 | $22 |
| AbbVie | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$1,525
- UroLift$287
- Proxis Ureteral Access Sheath$260
- UroLift System$195
- AMS 700 CXR RTE KIT$139
- Erleada$125
- STEGLATRO$103
- REZUM$103
How this compares
$4,100 in reported general payments places this provider in the 65th percentile of 122 urology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 48 | $778,630 |
| XtandiEnzalutamide | 12 | $173,201 |
| MyrbetriqMirabegron | 144 | $77,238 |
| Tamsulosin Hcl | 996 | $13,423 |
| Bicalutamide | 249 | $9,457 |
| Finasteride | 461 | $6,209 |
| Sildenafil Citrate | 207 | $4,364 |
| Tolterodine Tartrate ErTolterodine Tartrate | 75 | $4,277 |
| Oxybutynin Chloride ErOxybutynin Chloride | 228 | $4,263 |
| Darifenacin ErDarifenacin Hydrobromide | 27 | $4,156 |
| Tadalafil | 51 | $3,561 |
| NitrofurantoinNitrofurantoin Macrocrystal | 43 | $2,762 |
| Bethanechol Chloride | 28 | $2,648 |
| Levofloxacin | 187 | $2,371 |
| Estradiol | 30 | $2,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $578 | $778,63048 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $38 | $250,439156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 122 urology providers in Puerto Rico.
Other urology in Bayamon
- Ronald Cadillo ChavezBayamon$61K
- Omar Soto-AvilesBayamon$8K
- Hector Lopez HuertasBayamon$6K
- Jose Maymi RiveraBayamon$5K
- Raymond ChalokaBayamon$4K
- Jose Fournier RebolloBayamon$3K
- Patricia Maymi-CastrodadBayamon$3K
- Claudio Bernaschina BobadillaPonce$132K
- Mariela Martinez-RiveraPonce$105K
- Freddy Mendez TorresCayey$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.